All enrolled sufferers who acquired not less than one dose of zosuquidar or placebo throughout induction have been monitored to the occurrence of adverse events (439 people, 219 on zosuquidar and 210 on placebo). The most typical adverse activities have been connected with the period of prolonged and significant myelosuppression https://collinss998dpz1.azzablog.com/profile